Israel Stewart, DO
Internal Medicine · Rock Springs, WYNPI 1952624314
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 330 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AstraZeneca at 25.6% of the total. Among internal medicine clinicians in WY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 330 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$951
- AbbVie$731
- Novo Nordisk$529
- Grifols USA, LLC$376
- Lilly USA, LLC$344
- plus $1K from 23 others
What the payments were for
- Food & beverage$5,860100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 64 | $1,501 |
| GSK | 66 | $951 |
| AbbVie | 36 | $731 |
| Novo Nordisk | 35 | $529 |
| Grifols USA, LLC | 28 | $376 |
| Lilly USA, LLC | 22 | $344 |
| Amgen | 10 | $236 |
| Boehringer Ingelheim | 12 | $205 |
| Johnson & Johnson | 9 | $131 |
| Pfizer | 6 | $115 |
| Merck | 6 | $108 |
| Bayer | 5 | $80 |
| Viatris Specialty LLC | 4 | $64 |
| Pulmonx Corporation | 2 | $62 |
| Daiichi Sankyo Inc. | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 3 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Exact Sciences | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Vertex | 2 | $33 |
| Mylan Specialty L.p. | 2 | $32 |
| Verona Pharma, Inc. | 1 | $26 |
| Eisai Inc. | 2 | $26 |
| Dexcom, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Novartis | 1 | $20 |
| Sandoz | 1 | $18 |
| Sobi, Inc | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
How this compares
$5,865 in reported general payments places this provider in the 95th percentile of 101 internal medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 26 | $190,842 |
| Humira(Cf) PenAdalimumab | 12 | $163,480 |
| OzempicSemaglutide | 91 | $100,712 |
| EliquisApixaban | 162 | $87,456 |
| Humira(Cf)Adalimumab | 13 | $83,046 |
| MounjaroTirzepatide | 66 | $75,424 |
| FarxigaDapagliflozin Propanediol | 93 | $63,057 |
| BenlystaBelimumab | 12 | $56,309 |
| TrulicityDulaglutide | 58 | $55,646 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $39,020 |
| RybelsusSemaglutide | 25 | $31,207 |
| JardianceEmpagliflozin | 30 | $22,620 |
| XareltoRivaroxaban | 21 | $21,918 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $15,093 |
| Spiriva RespimatTiotropium Bromide | 20 | $13,462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $529 | $131,919116 claims |
| Lilly USA, LLCMounjaro, Trulicity | $344 | $131,070124 claims |
| PfizerEliquis | $115 | $87,456162 claims |
| AbbVieHumira(Cf), Synthroid | $731 | $86,17571 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere | $1,501 | $68,734106 claims |
| GSKBenlysta, Trelegy Ellipta | $951 | $68,01323 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $205 | $42,74762 claims |
| Johnson & JohnsonXarelto | $131 | $21,91821 claims |
| MerckJanuvia | $108 | $13,08614 claims |
| BayerKerendia | $80 | $7,37211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 internal medicine providers in Wyoming.
Other internal medicine in Rock Springs
- Terry DonaldsonRock Springs$1K
- Bryan ParadiseRock Springs$225
- Ahmad BashirimoghaddamRock Springs$105
- Michelle NeiceDouglas$4K
- David WalkerSheridan$3K
- Juli AckermanSheridan$3K
- Hannah HallSheridan$3K
- Kristopher SchamberSheridan$2K
- Julie CarlsonLaramie$2K
- John ThalkenDouglas$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.